Related Experiment Video
Updated: May 19, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Biomarkers and immune-modulating therapies for type 2 diabetes
Barbara Brooks-Worrell1, Radhika Narla, Jerry P Palmer
1Department of Medicine, University of Washington, VA Puget Sound Health Care System, Seattle, WA 98108, USA. bbrooks@u.washington.edu
Abstract:
Recent advances in understanding the etiology of obesity, metabolic syndrome, and type 2 diabetes (T2D) have established involvement of the immune system. These developments highlight the potential of immunomodulatory therapies for treatment of these conditions. Here, we discuss current and new immunotherapeutic strategies for the treatment of T2D, the need for stratification of patients based on immune and autoimmune status, and biomarkers for evaluating treatment efficiency. The time has come to re-evaluate the clinical management of T2D patients using metabolic parameters alone, and to realize that patients should be stratified based on their immune and/or autoimmune status prior to initiation of therapy to realize fully the potential of immunomodulatory strategies for T2D.
Related Concept Videos
Type I Diabetes II: Pathophysiology
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis